Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Digestive System and Liver›Malabsorption Syndromes

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Malabsorption Syndromes

Digestive System and Liver · NLM MeSH · updated 2026-11-04 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

General term for a group of malnutrition syndromes caused by failure of normal intestinal absorption of nutrients.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (894 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

General term for a group of malnutrition syndromes caused by failure of normal intestinal absorption of nutrients.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Malabsorption Syndrome; Syndrome, Malabsorption; Syndromes, Malabsorption.

Where it fits in the MeSH classification

Broader topics
Intestinal Diseases; Metabolic Diseases
Narrower topics
Blind Loop Syndrome; Celiac Disease; Collagenous Sprue; Lactose Intolerance; Short Bowel Syndrome; Sprue, Tropical; Steatorrhea; Whipple Disease; Hyperhomocysteinemia

Related concepts

  • Malnutrition
  • Intestinal Absorption

Research landscape

PubMed indexes 44,945 records tagged with the MeSH heading “Malabsorption Syndromes” (counts retrieved 2026-10-31). 5,626 of them (12.5%) were published from 2020 onward, and the busiest period so far is through 1999 with 19,073 records.

Reviews account for 7,249 records (16.1%) and meta-analyses for 325. Randomized controlled trials number 724 (1.6%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 19,073 records; 2000-2009: 9,829 records; 2010-2019: 10,417 records; 2020 onward: 5,626 records19,073through 19999,8292000-200910,4172010-20195,6262020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199919,073
2000-20099,829
2010-201910,417
2020 onward5,626
Share of records by publication typeReviews: 16.1 percent; Meta-analyses: 0.7 percent; Randomized controlled trials: 1.6 percentReviews16.1% (7,249)Meta-analyses0.7% (325)Randomized controlled trials1.6% (724)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 44,945 PubMed records
TypeRecordsShare
Reviews7,24916.1%
Meta-analyses3250.7%
Randomized controlled trials7241.6%

Method: PubMed query "Malabsorption Syndromes"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in digestive system and liver

Gut and liver research ranges from laboratory studies of the microbiome to large trials of drugs and surgery. Symptoms such as pain, reflux or bowel change are reported by patients and overlap between conditions, and diet and microbiome studies are mostly observational. Check whether the study measured symptoms, tissue findings or long-term outcomes, how the diagnosis was made and how long people were followed. Nothing here replaces advice from a qualified clinician.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Immune-epithelial-stromal networks define the cellular ecosystem of the small intestine in celiac disease
FitzPatrick MEB, Antanaviciute A, Dunstan M, Künnapuu K, Trzupek D, Provine NM, et al.
2025Research article
Design not recorded in structured metadata
21cc by
PMID 40328997 · DOI · PMC12133578
Study protocol of D1Ce Screen: A pilot project of the Italian national screening program for type 1 diabetes and coeliac disease in the paediatric population
Vincentini O, Pricci F, Silano M, Agrimi U, Iacoponi F, Villa M, et al.
2025Research article
Design not recorded in structured metadata
13cc by
PMID 40802787 · DOI · PMC12349695
Uncovering Hyperhomocysteinemia: Global Risk Patterns and Molecular Disruption in Brain and Vascular Health
Ramires Júnior OV, Prauchner GRK, Rieder AS, Leite AKO, Farias CP, Wyse ATS
2025Review article
Design not recorded in structured metadata
7cc by
PMID 41427720 · DOI · PMC12721006
The plasma metabolome and clinical features of patients with coeliac disease in Northwest China
Zhang W, Wu X, Li Y, Huang Z, Hui W, Shi T, et al.
2026Research article
Design not recorded in structured metadata
2cc by
PMID 42143209 · DOI · PMC13182154

Immune-epithelial-stromal networks define the cellular ecosystem of the small intestine in celiac disease [1]

Research article FitzPatrick MEB, Antanaviciute A, Dunstan M, Künnapuu K, Trzupek D, Provine NM, et al. · · 2025 · cited 21 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The immune-epithelial-stromal interactions underpinning intestinal damage in celiac disease (CD) are incompletely understood.
Closing excerpt
Receptor-ligand spatial analyses integrated with disease susceptibility gene expression defined networks of altered chemokine and morphogen signaling, and provide potential therapeutic targets for CD prevention and treatment.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (154 words)

The immune-epithelial-stromal interactions underpinning intestinal damage in celiac disease (CD) are incompletely understood. To address this, we performed single-cell transcriptomics (RNA sequencing; 86,442 immune, parenchymal and epithelial cells; 35 participants) and spatial transcriptomics (20 participants) on CD intestinal biopsy samples. Here we show that in CD, epithelial populations shifted toward a progenitor state, with interferon-driven transcriptional responses, and perturbation of secretory and enteroendocrine populations. Mucosal T cells showed numeric and functional changes in regulatory and follicular helper-like CD4+ T cells, intraepithelial lymphocytes, CD8+ and γδ T cell subsets, with skewed T cell antigen receptor repertoires. Mucosal changes remained detectable despite treatment, representing a persistent immune-epithelial 'scar'. Spatial transcriptomics defined transcriptional niches beyond those captured in conventional histological scores, including CD-specific lymphoid aggregates containing T cell-B cell interactions. Receptor-ligand spatial analyses integrated with disease susceptibility gene expression defined networks of altered chemokine and morphogen signaling, and provide potential therapeutic targets for CD prevention and treatment.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40328997 · DOI · PMC12133578

Study protocol of D1Ce Screen: A pilot project of the Italian national screening program for type 1 diabetes and coeliac disease in the paediatric population [2]

Research article Vincentini O, Pricci F, Silano M, Agrimi U, Iacoponi F, Villa M, et al. · · 2025 · cited 13 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundThe D1Ce Screen pilot study stems from the Italian Republic Law 130/2023 introducing the screening based on autoantibody measurement on capillary blood for the identification of people in pre-symptomatic, early phase of type 1 diabetes (T1D) and/or having silent celiac disease (CD) in the general paediatric population to reduce the impact of the two more frequent and severe chronic diseases of childhood.
Closing excerpt
Study registrationD1Ce Screen is not registered to any International Study Registry, as it is a pilot observational study requested by the Italian law 130/2023.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (337 words)

BackgroundThe D1Ce Screen pilot study stems from the Italian Republic Law 130/2023 introducing the screening based on autoantibody measurement on capillary blood for the identification of people in pre-symptomatic, early phase of type 1 diabetes (T1D) and/or having silent celiac disease (CD) in the general paediatric population to reduce the impact of the two more frequent and severe chronic diseases of childhood.AimPrimary aim is to assess, on a smaller scale, the organizational feasibility, acceptability and sustainability by the National Health Service of the screening program to be conducted nationwide in Italy according to the law.Methods and analysisThis is an observational multicenter study, planning to screen 5,363 children from four Italian regions (Lombardy, Marche, Campania, Sardinia), proportionally distributed according to population of the single Regions, representative of the North, Centre, South and Islands of Italy. Participants are screened by autoantibodies within three classes of age 2-2.9, 6-6.9, and 10-10.9 years, corresponding to reported peaks of seroconversion, in order to maximize the identification of future cases of disease. HLA typing for HLA DQ2 and DQ8 is also performed for CD risk in dry blood spots (DBS). Screening procedures are conducted by primary care paediatricians (PCPs), responsible for: direct contact with families; information about the study; administration of written informed consent, privacy statement and questionnaires; execution of blood drawing by finger prick; capillary blood collection for autoantibody and HLA testing and shipment to the central laboratory. Feasibility, acceptability and sustainability will be estimated by number of participating paediatricians; screened children in the four Regions and within the classes of age; feedback questionnaires; number of fingerpicks to obtain sufficient capillary blood for assays; any adverse events; costs evaluation in relation to assigned budget. Secondary objectives include frequency of T1D and CD specific autoantibodies to assess the prevalence of pre-symptomatic (Stage 1 and Stage 2) TD1 and undiagnosed CD in the three classes of age of general paediatric population.Study registrationD1Ce Screen is not registered to any International Study Registry, as it is a pilot observational study requested by the Italian law 130/2023.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40802787 · DOI · PMC12349695

Uncovering Hyperhomocysteinemia: Global Risk Patterns and Molecular Disruption in Brain and Vascular Health [3]

Review article Ramires Júnior OV, Prauchner GRK, Rieder AS, Leite AKO, Farias CP, Wyse ATS · · 2025 · cited 7 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Hyperhomocysteinemia (HHcy), a condition characterized by elevated plasma levels of the sulfur-containing amino acid homocysteine, has emerged as a multifactorial and systemic risk factor with profound effects on neural and vascular integrity.
Closing excerpt
By consolidating multidisciplinary evidence, we position HHcy as a pivotal but under-recognized target for intervention in neurochemical and vascular health.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (140 words)

Hyperhomocysteinemia (HHcy), a condition characterized by elevated plasma levels of the sulfur-containing amino acid homocysteine, has emerged as a multifactorial and systemic risk factor with profound effects on neural and vascular integrity. This review integrates recent findings from epidemiological studies, clinical data, and mechanistic research to provide a comprehensive overview of HHcy's contribution to neurovascular dysfunction. We examine how nutritional deficits, aging, genetic polymorphisms-such as in the methylenetetrahydrofolate reductase (MTHFR) and cystathionine beta-synthase (CBS) genes-pharmacological agents, and comorbid conditions shape homocysteine homeostasis and susceptibility to pathology. Emphasis is placed on molecular pathways, including oxidative and nitrative stress, inflammasome activation, autophagy, and epigenetic modulation, which link HHcy to cognitive decline, memory impairment, endothelial dysfunction, and increased disease burden in neurodegenerative disorders. By consolidating multidisciplinary evidence, we position HHcy as a pivotal but under-recognized target for intervention in neurochemical and vascular health.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41427720 · DOI · PMC12721006

The plasma metabolome and clinical features of patients with coeliac disease in Northwest China [4]

Research article Zhang W, Wu X, Li Y, Huang Z, Hui W, Shi T, et al. · · 2026 · cited 2 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
ObjectiveCoeliac disease (CeD) is a relatively common autoimmune disease in Caucasian populations, but is rarely reported in China.
Closing excerpt
This might underscore the multifactorial nature of coeliac disease, implicating other factors beyond genetics and gluten.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (263 words)

ObjectiveCoeliac disease (CeD) is a relatively common autoimmune disease in Caucasian populations, but is rarely reported in China. The metabolic characteristics of Chinese patients with coeliac disease remain insufficiently characterised. Therefore, this study attempted to describe the metabolic profile of a small cohort Chinese patients with coeliac disease.MethodsPlasma samples and dietary pattern information were collected from 15 patients with CeD, 15 healthy volunteers, and 30 patients with inflammatory bowel disease (IBD). Plasma metabolomic analysis was performed using a pseudo-targeted metabolomics approach based on ultra-high-performance liquid chromatography coupled with triple quadrupole-linear ion trap mass spectrometry (UHPLC-QTRAP-MS). Dietary intake was assessed via food frequency questionnaires, and metabolomics data were adjusted according to energy and 17 specific nutrient covariates.ResultsDespite reporting significantly higher daily intakes of protein and carbohydrate when compared to controls or IBD patients, CeD patients exhibited a relative insufficiency of micronutrient niacin. Several distinct metabolic alterations were identified in CeD patients relative to healthy controls, independent of dietary intake. These included decreased metabolites in the pentose phosphate pathway and increased intermediates of the citric acid cycle. The abundances of L-proline, D-proline, microbiota-related aromatic amino acid metabolites, glycine-conjugated bile acids, and the plant sterol panuosterone were increased. In contrast, the abundances of several long-chain acylcarnitines were reduced despite higher fat intake. These metabolic alterations existed in CeD but not in IBD patients.ConclusionsCeD patients in Northwest China exhibit a unique metabolic profile distinct from IBD and healthy controls, involving host central carbon metabolism, glycerophospholipid metabolism, gut microbiota, and other factors. This might underscore the multifactorial nature of coeliac disease, implicating other factors beyond genetics and gluten.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42143209 · DOI · PMC13182154

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis [5]
    Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. · Clin Gastroenterol Hepatol · 2018 · cited 1,072 times (Europe PMC)
  • Research article Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis [6]
    King JA, Jeong J, Underwood FE, Quan J, Panaccione N, Windsor JW, et al. · Am J Gastroenterol · 2020 · cited 308 times (Europe PMC)
  • Research article Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis [7]
    Storhaug CL, Fosse SK, Fadnes LT · Lancet Gastroenterol Hepatol · 2017 · cited 233 times (Europe PMC)
  • Research article Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease [8]
    Ray JG · Arch Intern Med · 1998 · cited 215 times (Europe PMC)
  • Research article Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis [9]
    Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK · Fertil Steril · 2000 · cited 173 times (Europe PMC)
  • Research article Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea [10]
    Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD · Aliment Pharmacol Ther · 2015 · cited 152 times (Europe PMC)

References

  1. FitzPatrick MEB, Antanaviciute A, Dunstan M, Künnapuu K, Trzupek D, Provine NM, et al.. Immune-epithelial-stromal networks define the cellular ecosystem of the small intestine in celiac disease. . 2025. PMID 40328997 · DOI · PMC12133578
  2. Vincentini O, Pricci F, Silano M, Agrimi U, Iacoponi F, Villa M, et al.. Study protocol of D1Ce Screen: A pilot project of the Italian national screening program for type 1 diabetes and coeliac disease in the paediatric population. . 2025. PMID 40802787 · DOI · PMC12349695
  3. Ramires Júnior OV, Prauchner GRK, Rieder AS, Leite AKO, Farias CP, Wyse ATS. Uncovering Hyperhomocysteinemia: Global Risk Patterns and Molecular Disruption in Brain and Vascular Health. . 2025. PMID 41427720 · DOI · PMC12721006
  4. Zhang W, Wu X, Li Y, Huang Z, Hui W, Shi T, et al.. The plasma metabolome and clinical features of patients with coeliac disease in Northwest China. . 2026. PMID 42143209 · DOI · PMC13182154
  5. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al.. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018. PMID 29551598 · DOI
  6. King JA, Jeong J, Underwood FE, Quan J, Panaccione N, Windsor JW, et al.. Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2020. PMID 32022718 · DOI
  7. Storhaug CL, Fosse SK, Fadnes LT. Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017. PMID 28690131 · DOI
  8. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998. PMID 9801176 · DOI
  9. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril. 2000. PMID 11119750 · DOI
  10. Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015. PMID 25913530 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-11-04.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • SteatorrheaDigestive System and Liver
  • Celiac DiseaseDigestive System and Liver
  • Lactose IntoleranceRare and Inherited Diseases
  • IleusDigestive System and Liver
  • Intestinal ObstructionDigestive System and Liver
  • PouchitisDigestive System and Liver

All 66 articles in Digestive System and Liver →

At a glance

44,945
PubMed records on this heading
13%
published since 2020
7,249
review articles
724
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • SteatorrheaDigestive System and Liver
  • Celiac DiseaseDigestive System and Liver
  • Lactose IntoleranceRare and Inherited Diseases
  • IleusDigestive System and Liver
  • Intestinal ObstructionDigestive System and Liver

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support